ResVerlogix cholesterol drug fails mid-stage trial
November 17, 2010 at 15:13 PM EST
Nov 17 (Reuters) - ResVerlogix's experimental drug failed to achieve its main goal of increasing production of protein associated with good cholesterol and clear plaque from arteries, sending its shares down as much as 45 percent.